|
|
|
ACHN - Achillion Pharmaceuticals, Inc.
Achillion
Pharmaceuticals, Inc. (ACHN) is a clinical-stage biopharmaceutical
company that is focused on the development of small molecule drugs to
treat immune system disorders and viral infections, including
hepatitis C.
Achillion Pharmaceuticals is primarily focused on
the development of oral small molecule drugs for the treatment of
immune system disorders and viral infections. The company's lead drug
candidate is danicopan (ACH-4471), which is being developed for the
treatment of complement-mediated diseases.
In addition, the
company has a pipeline of drug candidates for the treatment of viral
infections, including hepatitis C. Achillion Pharmaceuticals has
previously developed several drugs for the treatment of hepatitis C,
including sovaprevir and odalasvir, which were later licensed to other
companies.
The company has reported financial results for the
third quarter of 2021, reporting a net loss of $15.2 million, compared
to a net loss of $19.4 million in the same period in the previous
year. Achillion Pharmaceuticals reported cash, cash equivalents, and
marketable securities of $254.5 million as of September 30, 2021.
Achillion Pharmaceuticals has been focused on advancing its
pipeline of drug candidates and entering into partnerships and
collaborations with other companies. In October 2021, the company
announced that it had entered into a strategic collaboration with
Pandion Therapeutics to develop novel immune modulators for the
treatment of autoimmune and inflammatory diseases.
However, the
company's financial performance and operations may be impacted by
various factors, including the outcome of clinical trials, regulatory
changes, and competition in the biopharmaceutical industry. In
addition, the ongoing COVID-19 pandemic may continue to cause
disruptions in the global economy and the healthcare industry, which
may affect Achillion Pharmaceuticals' operations and financial
results.
Overall, Achillion Pharmaceuticals, Inc. is a
clinical-stage biopharmaceutical company that is focused on the
development of small molecule drugs to treat immune system disorders
and viral infections. The company has a pipeline of drug candidates
and has entered into partnerships and collaborations to advance its
research and development efforts. However, the company's financial
performance and operations are subject to various risks and
uncertainties associated with the biopharmaceutica
|
|
|
|
|
